Chiesi Pharmaceuticals announced a $1.9 billion all-cash tender offer for KalVista Pharmaceuticals at $16.00 per share, a 168% premium to the $5.97 close on April 11. The Parma-based rare disease specialist is acquiring sebetralstat, an oral plasma kallikrein inhibitor in Phase 3 trials for hereditary angioedema, plus KalVista's earlier-stage complement pipeline. Tender documents file within three business days.
KalVista's market capitalization sat at $709 million before the announcement. Chiesi is paying 2.68x that figure for a single late-stage asset and platform technology around bradykinin-mediated disease. Sebetralstat posted positive topline data in its KONFIDENT trial in November 2024, meeting primary endpoints for HAE attack treatment with onset of relief at 1.73 hours versus 3.08 hours for placebo. The drug competes with Takeda's Takhzyro, BioCryst's Orladeyo, and Pharming's Ruconest in a global HAE market sized at $4.2 billion in 2023 and growing at 8-11% annually. Chiesi already markets Jorveza for eosinophilic esophagitis and holds commercial infrastructure across 31 countries.
The premium reflects two realities. First, oral kallikrein inhibitors represent the current standard-of-care direction in HAE, replacing subcutaneous prophylaxis. Second, family-office-backed pharmaceutical acquirers pay different multiples than public strategics when the asset aligns with stated portfolio adjacencies. Chiesi's rare disease unit posted €1.8 billion in 2023 revenue, roughly 40% of group sales. Sebetralstat, if approved, slots into existing neuromuscular and immunology sales channels without infrastructure build. The acquisition also removes clinical and regulatory risk from KalVista's balance sheet eighteen months before the PDUFA decision window, which matters when your buyer has €2.3 billion in net cash and no earnings call to manage.
Allocators should mark three follow-on events. Tender close is expected within 45-60 days assuming HSR clearance and no competing bid, which is unlikely given KalVista's 94% institutional ownership and signed lock-up agreements covering 23% of shares. FDA decision on sebetralstat's NDA, filed in Q4 2024, lands in Q3 2025 under standard review. Finally, Chiesi's broader M&A appetite becomes visible when a private company moves $1.9 billion in cash this cleanly—watch for follow-on tuck-ins in complement biology or bradykinin pathways where acquire-to-build makes sense at $500 million to $1.2 billion enterprise values. The Chiesi family has deployed $4.7 billion in acquisitions since 2019, and sebetralstat represents the largest single check.
KalVista's oral competitor landscape now consolidates into three players: BioCryst's existing Orladeyo franchise at $468 million trailing twelve-month sales, Pharvaris's delineated PH-1 program in Phase 3, and now Chiesi-owned sebetralstat with a 2026 launch timeline and European commercial reach already built.